Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q1 2025 vs. Q4 2024
How the institutions holding Damora Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 10 | 11 | +1 |
| Shares | 142.1K | 142.7K | +639 (+0.4%) |
| Value | $660.7K | $442.4K | −$218.3K (−33.0%) |
New holders (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 10,722 | $33.2K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,583 | $4.91K | 0.00% |
| Barclays PLC | 133 | $412 | 0.00% |
Sold out (2)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| JPMorgan Chase & Co | 100 | $466 |
| Morgan Stanley | 100 | $465 |